Cocrystal Pharma Doses First Subjects in Phase 1b Norovirus Trial — Cocrystal Pharma, Inc.

Event summary

First subjects dosed in Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 for prevention and treatment.
Study conducted at Emory University School of Medicine, enrolling up to 40 healthy subjects aged 18–49.
CDI-988 is the first oral antiviral drug candidate developed specifically for norovirus acute gastroenteritis.
Norovirus causes 685 million global cases annually with a $60 billion economic impact.

The big picture

Cocrystal Pharma’s Phase 1b trial for norovirus represents a critical step in addressing a significant unmet medical need, with no approved treatments or vaccines currently available. The global economic burden of norovirus, estimated at $60 billion annually, underscores the potential market opportunity for CDI-988 if proven effective. Success in this trial could validate Cocrystal’s structure-based drug discovery platform and position it as a key player in antiviral therapeutics.

What we're watching

Clinical Efficacy: Whether CDI-988 demonstrates sufficient efficacy in reducing norovirus symptoms and viral shedding compared to placebo.
Regulatory Pathway: The pace at which Cocrystal can advance CDI-988 through subsequent clinical phases following Phase 1b results.
Market Opportunity: How Cocrystal positions CDI-988 in high-risk environments like hospitals and cruise ships to capture market share.